Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14533305 | 0.72 | PTGS1 (0.30) | — | |
| SCHEMBL20288249 | 0.64 | MEN1 (0.38) | PTPN1 | |
| SCHEMBL20288559 | 0.63 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL12851540 | 0.61 | TOP2A (0.31) | — | |
| SCHEMBL14415255 | 0.59 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL7637933 | 0.58 | — | — | |
| SCHEMBL3413343 | 0.58 | CDC25A (0.37) | PTPN1 | |
| SCHEMBL12121173 | 0.57 | — | — | |
| SCHEMBL820849 | 0.55 | LMNA (0.32) | PTPN1 | |
| SCHEMBL13092048 | 0.54 | PTPN1 (0.31) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | PTPN1 835/4885 |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | PTGS2, FAAH2, PTGES2 | PTPN1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.